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Redox homeostasisThe brain has high energy requirements to maintain neuronal activity. Consequently impaired mitochondrial
function will lead to disease. Normal aging is associated with several alterations in neurosteroid production
and secretion. Decreases in neurosteroid levels might contribute to brain aging and loss of important nervous
functions, such as memory. Up to now, extensive studies only focused on estradiol as a promising neurosteroid
compound that is able to ameliorate cellular bioenergetics, while the effects of other steroids on brainmitochon-
dria are poorly understood or not investigated at all. Thus, we aimed to characterize the bioenergeticmodulating
proﬁle of a panel of seven structurally diverse neurosteroids (progesterone, estradiol, estrone, testosterone,
3α-androstanediol, DHEA and allopregnanolone), known to be involved in brain function regulation. Of note,
most of the steroids tested were able to improve bioenergetic activity in neuronal cells by increasing ATP levels,
mitochondrial membrane potential and basal mitochondrial respiration. In parallel, they modulated redox ho-
meostasis by increasing antioxidant activity, probably as a compensatory mechanism to a slight enhancement
of ROS which might result from the rise in oxygen consumption. Thereby, neurosteroids appeared to act via
their corresponding receptors and exhibited speciﬁc bioenergetic proﬁles. Taken together, our results indicate
that the ability to boost mitochondria is not unique to estradiol, but seems to be a rather common mechanism
of different steroids in the brain. Thus, neurosteroids may act upon neuronal bioenergetics in a delicate balance
and an age-related steroid disturbance might be involved inmitochondrial dysfunction underlying neurodegen-
erative disorders.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The brain is a highly differentiated organ with high energy require-
ments, mainly in the form of adenosine triphosphate (ATP) molecules.
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. This is an open access article underoxygen consumption [1]. As a result, the brain is more sensitive to neuro-
nal damage during hypometabolic states and impaired redox homeosta-
sis, as observed in normal aging and in neurodegenerative diseases
associated with a decline in energy production and changes in the
redox status [2]. In this context, mitochondria, small organelles that are
present in almost all cell types playing a predominant role in cellular bio-
energetics, are particularly important in the nervous systembecause of its
high energy demand. Mitochondria are not only the “powerhouses of the
cell”, providing the main source of cellular energy via ATP generation
through oxidative phosphorylation, but they also contribute to plenty of
cellular functions, including apoptosis, intracellular calcium homeostasis,
alteration of the cellular reduction–oxidation (redox) state and synaptic
plasticity [3,4]. Thus, it is more and more recognized that mitochondrial
dysfunction is a signiﬁcant and early event of neurodegeneration, and
that the pathophysiological mechanisms of a range of neurodegenerative
diseases, including Alzheimer's (AD) and Parkinson's disease (PD), are as-
sociated with a decline in bioenergetic activity and an increase in oxida-
tive stress, particularly in mitochondria themselves [5–10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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physiological processes in the periphery, from reproductive behavior
to the stress response. They are mainly produced by endocrine glands,
such as the adrenal glands, gonads and placenta, but in 1981 Baulieu
and co-workerswere the ﬁrst to demonstrate the production of steroids
within the nervous system itself [11]. This last category of molecules
is now called “neurosteroids” and is deﬁned as steroids that are
synthetized within the nervous system independently of peripheral
endocrine glands. Neurosteroid levels remain elevated even after adre-
nalectomy and castration [12,13] and are involved in brain-speciﬁc
functions. Since the ability to produce neurosteroids is conserved during
vertebrate evolution, one can suggest that this family ofmolecules is im-
portant for living things and that the modulation of their biosynthesis
plays an important role in the pathophysiology of neurodegenerative
disorders.
Studies performed in humans, animals, and cellular models have
shown alterations in the synthesis of neurosteroids that declined during
brain aging paralleled by a loss of important nervous functions, such as
memory, and were further associated with PD and AD [14–16]. Thus,
several neurosteroids have been quantiﬁed in various brain regions of
aged AD patients and aged non-demented controls. This showed a gener-
al trend toward lower steroid levels in AD patients compared to controls,
associated with a negative correlation between neurosteroid levels and
amyloid-β (Aβ) and phospho-tau in some brain regions [17]. In accor-
dance with these observations, previous data from our groups provided
ﬁrst evidence that, vice versa, Aβ and hyperphosphorylated tau differen-
tially impacted neurosteroidogenesis (Fig. 1) [18–20]. Indeed, a decrease
of progesterone and 17-hydroxyprogesterone production was observed
in amyloid precursor protein (APP)/Aβ-overexpressing cells, while 3α-
androstanediol and estradiol levels were increased [19]. Moreover,
in vitro treatment of humanneuroblastoma cellswith “non-toxic”Aβ con-
centrations (within the nanomolar range) revealed an increase in estradi-
ol production, whereas toxic Aβ concentrations (within the micromolar
range) showed the opposite effect [18]. Overexpression of human wild
type tau (hTau40) protein induced an increase in productionof progester-
one, 3α-androstanediol, and 17-hydroxyprogesterone, in contrast to the
abnormally hyperphosphorylated tau bearing the P301L mutation that
led to decreased production of these neurosteroids [19].
Moreover, a growing body of evidence has highlighted neuropro-
tective effects of steroids, particularly estradiol, against AD-related
injury (reviewed in [21]). Because the drop of estrogen in a post-
menopausal woman is considered as a risk factor in AD (two-thirds
of AD patients are women), the neuroprotective action of estrogen
has been widely investigated (reviewed in [22]). One in vivo studyFig. 1. Schematic representation of the main biochemical pathways for neurosteroidogenesi
neurosteroids whose synthesis is impacted in AD. PREG; pregnenolone, PROG; progesterone
dehydroepiandrosterone, DHP; dihydroprogesterone, ALLOPREG; allopregnanolone, DHT; dih
cytochrome P450c17, 3β-HSD; 3β-hydroxysteroid dehydrogenase, 5α-R; 5α-reductase, Arom
17β-HSD; 17β-hydroxysteroid dehydrogenase.showed that estradiol treatment of ovariectomized female rats up-
regulated enzymes involved in glycolysis and oxidative phosphory-
lation, and increased ATP synthase expression which was translated
into an increased mitochondrial respiration [23]. These ﬁndings
were additionally conﬁrmed in an AD mouse model by Yao and co-
workers [24].
However, there is little evidence that other steroids are also able to
act on mitochondrial function, and to our knowledge, no study has
aimed to compare the effects of neurosteroids besides estradiol on
cellular bioenergetics and redox environment in neuronal cells. Thus,
the objective of our study was to investigate the effects of different
neurosteroids on bioenergetic activity in vitro. For this purpose, we se-
lected seven neurosteroids — progesterone, estradiol and estrone, be-
longing to the estrogen family; testosterone and 3α-androstanediol,
belonging to the androgen family; and DHEA and allopregnanolone —
known to be involved in brain function regulation [12,13,17–19,25].
Neurosteroid effects onATP production,mitochondrialmembrane poten-
tial (MMP), mitochondrial respiration, glycolysis and the consequences
on themodulation of the redox environment were investigated in neuro-
nal cells.
2. Materials and methods
2.1. Chemicals and reagents
Dulbecco's-modiﬁed Eagle'smedium (DMEM), RPMI-1640medium,
fetal calf serum (FCS), penicillin/streptomycin, progesterone, 17β-
estradiol, estrone, 3α-androstanediol, DHR, TMRM, ADP, pyruvate, suc-
cinate and malate were from Sigma-Aldrich (St. Louis, MO, USA).
Glutamax, MitoSOX, DPBS, neurobasal medium and B27 were from
Gibco Invitrogen (Waltham, MA, USA). DHEA and allopregnanolone
were from Calbiochem (Billerica, MA, USA). PMP and XF Cell Mitostress
kit were from Seahorse Bioscience (North Billerica,MA, USA). Testoster-
one was from AppliChem (Darmstadt, Germany). Horse serum (HS)
was from Amimed, Bioconcept (Allschwil, Switzerland). RU-486, ICI-
187.780, and 2-hydroxy ﬂutamide were from Cayman Chemical (Ann
Arbor, MI, USA).
2.2. Cell culture
Human SH-SY5Y neuroblastoma cells were grown at 37 °C in a hu-
midiﬁed incubator chamber under an atmosphere of 7.5% CO2 in DMEM
supplemented with 10% (v/v) heat-inactivated FCS, 5% (v/v) heat-
inactivated HS, 2 mM Glutamax and 1% (v/v) penicillin/streptomycin.s in the vertebrate brain. Boxes represent neurosteroids tested in our study. * indicates
, 17OH-PREG; 17-hydroxypregnenolone, 17OH-PROG; 17-hydroxyprogesterone, DHEA;
ydrotestosterone, P450scc; cytochrome P450 cholesterol side chain cleavage, P450c17;
.; aromatase, 21-OHase; 21-hydroxylase, 3α-HSOR; 3α-hydroxysteroid oxydoreductase,
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they reached 80–90% conﬂuence.
2.3. Primary neuronal cultures
Mouse cortical neurons were prepared from E15 embryos according
to the French guidelines, as previously described [26]. Cells were plated
in poly-L-lysine-coated plates at a density of 1.5 × 104 cells/well for ATP
measurement (white 96-well plate) or 5 × 104 cells/well for measure-
ment with the Seahorse XF24 Analyser (XF24 cell culture microplate).
After 7 days at 37 °C, 50% of the medium was replaced with fresh
medium every third day. ATP level, oxygen consumption rate (OCR)
and extracellular acidiﬁcation rate (ECAR) were investigated in this
primary neuronal culture after a 24 h treatment with the different
neurosteroids.
2.4. Treatment paradigm
Assessment of cell viability was performed on SH-SY5Y neuro-
blastoma cells to determine the potential toxic concentration range of
neurosteroids (from 10 nM to 1000 nM, data not shown) and steroid re-
ceptor antagonists (SRA, from1nM to 1 μM, data not shown) using aMTT
reduction assay (Roche, Basel, Switzerland). On the basis of the MTT re-
sults, the concentrations 10 nM and 100 nM of steroids were then select-
ed and used in all assays. SH-SY5Y cells were treated one day after plating
either with DMEM (untreated control condition) or with a ﬁnal concen-
tration of 10 nM and 100 nM of progesterone, 17β-estradiol, estrone, tes-
tosterone, 3α-androstanediol, DHEA or allopregnanolone made from a
stock solution in DMSO for 24 h (ﬁnal concentration of DMSO b 0.002%,
no effect of the vehicle solution (DMSO) alone compared to the untreated
condition). In the experiment using SRA, cells were pre-treated for 1 h
with 100nMofRU-486and ICI-187.780, and1 μMof 2-hydroxyﬂutamide
(2OH-ﬂutamide), and then treated for 24 h with the corresponding
neurosteroids. To limit cell growth and to optimizemitochondrial respira-
tion, treatment medium contained only a low amount of fetal calf serum
(5% FCS) as well as glucose (1 g/l) andwas supplementedwith 4mMpy-
ruvate. Each assay was repeated at least 3 times.
2.5. ATP levels
Total ATP content of SH-SY5Y cells was determined using a biolumi-
nescence assay (ViaLighTM HT, Cambrex Bio Science, Walkersville, MD,
USA) according to the instruction of the manufacturer, as previously
described [27]. SH-SY5Y cells were plated in 5 replicates into a white
96-well cell culture plate at a density of 1.5 × 104 cells/well. The biolu-
minescent method measures the formation of light from ATP and lucif-
erin by luciferase. The emitted light was linearly related to the ATP
concentration and was measured using the multilabel plate reader
VictorX5 (Perkin Elmer).
2.6. Cell proliferation assay
To verify if our treatment had an impact on cell cycle and induced
proliferation, the BrdU Cell Proliferation Assay (Calbiochem, Darmstadt,
Germany) was used following the instructions of the manufacturer.
Brieﬂy, SH-SY5Y cells were plated in 6 replicates into a 96-well cell
culture plate at a density of 1 × 104 cells/well. During the ﬁnal 12 h of
neurosteroid treatment, BrdU was added to the wells and incorporated
into the DNA of dividing cells. The detection of BrdU was performed
using an anti-BrdU antibody recognized by a horseradish peroxidase-
conjugated anti-mouse. After addition of the substrate (TMB), the
color reaction was quantiﬁed using the multilabel plate reader
VictorX5 at 450 nm. Values are proportional to the number of divid-
ing cells.2.7. Determination of mitochondrial membrane potential
The MMP was measured using the ﬂuorescent dye tetramethyl-
rhodamine, methyl ester, and perchlorate (TMRM). SH-SY5Y cells
were plated in 6 replicates into a black 96-well cell culture plate at a
density of 1.5 × 104 cells/well. Cells were loaded with the dye at a con-
centration of 0.4 μM for 15 min. After washing twice with HBSS, the
ﬂuorescence was detected using the multilabel plate reader VictorX5
(PerkinElmer) at 530 nm (excitation)/590 nm (emission). Transmem-
brane distribution of the dye was dependent on MMP.
2.8. Oxygen consumption rate and extracellular acidiﬁcation rate
The Seahorse Bioscience XF24Analyserwas used to performa simul-
taneous real-timemeasurement of oxygen consumption rate (OCR) and
extracellular acidiﬁcation rate (ECAR). XF24 cell culture microplates
(Seahorse Bioscience) were coated with 0.1% gelatine and SH-SY5Y
cells were plated at a density of 2.5 × 104 cells/well in 100 μl of the treat-
mentmediumcontaining5% FCS, 1 g/l glucose and 4mMpyruvate. After
neurosteroid treatment, cells were washed with PBS and incubated
with 500 μl of assay medium (DMEM, without NaHCO3, without phenol
red, with 1 g/l glucose, 4 mM pyruvate, and 1% L-glutamine, pH 7.4) at
37 °C in a CO2-free incubator for 1 h. The plate was placed in the XF24
Analyser and basal OCR and ECARwere recorded during 30min. For pri-
mary neuronal culture, the same conditions were kept, except the me-
dium; here DMEMwas replaced by RPMI-1640 medium.
2.9. Mitochondrial respiration
The investigation of mitochondrial respiration was performed using
the Seahorse Bioscience XF24 Analyser. XF24 cell culture microplates
were coated with 0.1% gelatine and cells were plated at a density of
2.5 × 104 cells/well in 100 μl of treatment medium containing 5% FCS,
1 g/l glucose and 4 mM pyruvate. After neurosteroid treatment, cells
were washed with 1× pre-warmed mitochondrial assay solution
(MAS; 70 mM sucrose, 220 mM mannitol, 10 mM KH2PO, 4.5 mM
MgCl2, 2 mM HEPES, 1 mM EGTA and 0.2% (w/v) fatty acid-free BSA,
pH 7.2 at 37 °C) and 500 μl of pre-warmed (37 °C) MAS containing
1 nM XF plasma membrane permeabilizer (PMP, Seahorse Bioscience),
10 mM pyruvate, 10 mM succinate and 2 mM malate was added to
the wells. The PMP was used to permeabilize intact cells in culture,
which circumvents the need for isolation of intact mitochondria and al-
lows the investigation of the OCR under different respiratory states in-
duced by the sequential injection of: i) ADP (4 mM) to induce state 3;
ii) oligomycin (0.5 μM) to induce state 4o; iii) FCCP (2 μM) to induce
state 3 uncoupled (3u); and iv) antimycin A/rotenone (0.5 μM and
1 μM respectively) to shut down mitochondrial respiration. Data were
extracted from the Seahorse XF24 software and the respiratory control
ratio (RCR: state 3/state 4o), which reﬂects themitochondrial respirato-
ry capacity, was calculated.
2.10. GABAA receptor expression
Cells were lysed and total RNA was extracted using the RNeasy Mini
Kit from Qiagen (Venlo, Netherlands), according to the instructions of
the manufacturer to measure GABAA receptor (subunits α1 and β2)
mRNA levels. The ﬁrst cDNA strand was synthesized using all RNA ex-
tracted by reverse transcription in a ﬁnal volume of 30 μl using the
Ready-to-Go You-Prime First-Strand Bead cDNA synthesis kit (GE
Healthcare, Little Chalfont, UK) according to the supplied protocol.
After reverse transcription, the cDNAwas diluted 1:3 and 3 μl were am-
pliﬁed by real-time PCR (StepOne™ System) in 20 μl using DyNAmy
Flash Probe qPCR Kit (Thermo Scientiﬁc, Waltham, MA, USA) with
conventional Applied Biosystems cycling parameters (40 cycles of 95 °C,
5 s, and 60 °C, 1 min). Primers for human and mouse GABAA receptor
subunit α1 and β2 were obtained from Life Technologies (Waltham,
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GABRB2: Hs00241451_m1; gabra1: Mm00439046_m1; and gabrb2:
Mm00433467_m1. After ampliﬁcation, the size of the quantitative
real-time PCR products was veriﬁed by electrophoresis on 2% (wt/vol)
ethidium bromide-stained agarose gel. CDK4 was used as control house-
keeping gene to assess the validity of the cDNAmixture and the PCR reac-
tion. The gene expression of CDK4was clearly detected in SH-SY5Y (data
not shown), but not that of GABAA receptor.
2.11. Reactive oxygen species detection
Total level of mitochondrial reactive oxygen species (mtROS) and
speciﬁc level of mitochondrial superoxide anion radicals were assessed
using the ﬂuorescent dye dihydrorhodamine 123 (DHR) and the Red
Mitochondrial Superoxide Indicator (MitoSOX), respectively. SH-SY5Y
cells were plated in 6 replicates into a black 96-well cell culture plate
at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells
were loaded with 10 μM of DHR for 15 min or 5 μM of MitoSOX for
90 min at room temperature in the dark on an orbital shaker. After
washing twice with HBSS (Sigma), DHR, which is oxidized to cationic
rhodamine 123 localizedwithin themitochondria, exhibits a greenﬂuo-
rescence that was detected using themultilabel plate reader VictorX5 at
485 nm (excitation)/538 nm (emission). MitoSOX, which is speciﬁcally
oxidized by mitochondrial superoxide, exhibits a red ﬂuorescence
detected at 535 nm (excitation)/595 nm (emission). The intensity of
ﬂuorescence was proportional to mtROS levels or superoxide anion
radicals in mitochondria.
2.12. MnSOD activity
The DetectX Superoxide Dismutase (SOD) Activity Kit (Ann Arbor, MI,
USA) was used to quantitatively measure manganese SOD (MnSOD) ac-
tivity following the instructions of the manufacturer. Brieﬂy, 1 × 106
SH-SY5Y cells were collected for protein extraction. After a short sonica-
tion in PBS, the cellular homogenate was centrifuged at 1500 ×g for
10 min at 4 °C. The supernatant was then centrifuged at 10,000 ×g for
15min and the obtained cell pellet was treatedwith 2mMpotassium cy-
anide, and assayed for MnSOD activity.
2.13. Mitochondrial redox environment
To investigate changes in mitochondrial redox environment,
SH-SY5Y cells were transfectedwith a plasmid coding for a redox sensi-
tive green ﬂuorescent protein with a mitochondrial targeting sequence
(pRA305 in pEGFP-N1). In an oxidized environment the absorption in-
creases at short wavelengths (390 nm) at the expense of absorption at
longer wavelengths (485 nm). The ﬂuorescence ratio indicates oxida-
tion/reduction, i.e., the redox environment in the mitochondria [28].
Cells were plated in 6 replicates into a black 96-well cell culture plate
at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells
were washed twice with PBS and placed in a HEPES buffer (130 mM
NaCl, 5 mM KCl, 1 mM CaCl2, 10 mM D-glucose, and 20 mM HEPES).
The ratio 390 nm/485 nm was measured using the multilabel plate
reader VictorX5 detecting ﬂuorescence at 390 nm or 485 nm (excita-
tion)/510 nm (emission). An increase of the ratio indicates a more
oxidized environment.
2.14. Statistical analysis
Data are given as themean±SEM, normalized to the untreated con-
trol group (=100%). Statistical analyses were performed using the
Graph Pad Prism software. For statistical comparisons of more than
two groups, One-way ANOVAwas used, followed by Dunnett's multiple
comparison test versus the control. For statistical comparisons of two
groups, Student unpaired t-test was used. P values b 0.05 wereconsidered statistically signiﬁcant. Statistical correlations were deter-
mined using Pearson's correlation coefﬁcients.
3. Results
3.1. Neurosteroids modulate mitochondrial bioenergetics
To investigate the effects of neurosteroids on cellular bioenergetic
activity, we ﬁrst studied the SH-SY5Y cell line, a commonly used neuro-
nal culture in vitromodel that expresses a variety of neuronal receptors,
including steroid receptors (progesterone, estrogen and androgen
receptors) [29,30]. Cells were treated with different neurosteroids:
progesterone (P), estradiol (E2), estrone (E1), testosterone (T), 3α-
androstanediol (3α-A), DHEA (D) or allopregnanolone (AP), at two
physiologically relevant concentrations, 10 nM and 100 nM [31–35],
and ATP level was measured after 24 h of treatment. All neurosteroids,
except allopregnanolone, were able to signiﬁcantly increase ATP level
(Fig. 2A), ranging from a 10% increase after 3α-A treatment (10 nM)
up to a 22% increase induced by progesterone (100 nM) compared to
the untreated control.
A pre-treatment for 1 h with different steroid receptor antago-
nists (SRA) including the progesterone receptor antagonist RU-486
(assay concentration 100 nM), the estrogen receptor antagonist
ICI-182.780 (assay concentration 100 nM), and the androgen recep-
tor antagonist 2OH-ﬂutamide (assay concentration 1 μM) complete-
ly abolished the action of P, E2 and E1, as well as T and 3α-A,
respectively (Fig. 2B). The SRAs alone were devoid of the effects of ATP
production. These results indicate that the action of neurosteroids may
be mediated by nuclear receptors via gene regulation, at least for those
neurosteroids that act via these receptors (progesterone, estrogens, and
androgens).
To exclude that this rise in ATP was due to enhanced cell prolifera-
tion, we investigated the effects of the different neurosteroids. Of note,
only allopregnanolone at 100 nM induced a signiﬁcant increase of cell
division by about 6% compared to the control (Table 1). Thus, our results
indicate that the neurosteroid-induced up-regulation of cellular energy
levels was independent of cell proliferation demands.
To verify whether the increase of ATP levels was directly linked to
mitochondrial activity, we investigated the effects of neurosteroids on
MMP, an indicator of the protonmotive force necessary for ATP synthe-
sis by the mitochondrial ATP synthase [36]. Our results show that, at
least for one of the two concentrations tested, neurosteroids induced a
signiﬁcant increase in MMP (Fig. 2C). The low concentration of 10 nM
was particularly effective, ranging from an 18% increase after estradiol
treatment up to a32% increase inducedbyDHEA.Again, allopregnanolone
was not able to signiﬁcantly modulate the MMP. Thus, the observed in-
crease in ATP is consistent with the ﬁnding of a slight hyperpolarization
of the MMP.
Because molecules of ATP are produced by two main pathways, the
cellular glycolysis and oxidative phosphorylation (OXPHOS) in mito-
chondria, we determined whether and which of those neurosteroids
were able to modulate one or both pathways. For this purpose, we si-
multaneously monitored in real-time the extracellular acidiﬁcation
rate (ECAR), an indicator of glycolysis, and the oxygen consumption
rate (OCR), an indicator of basal respiration, using a Seahorse Bioscience
XF24 Analyser (Fig. 3A–C). On the one hand, despite a slight general in-
crease, only estradiol and DHEAwere able to signiﬁcantly modulate the
ECAR after 24 h of treatment (about 16.4% and 19.4% respectively)
(Fig. 3A). On the other hand, ourﬁndings demonstrate that estradiol, es-
trone, testosterone, 3α-A and DHEA signiﬁcantly increased the OCR,
with the most pronounced effect detected after a testosterone treat-
ment at 100 nM (+26.5% compared to the control) (Fig. 3B). To com-
pare the action of neurosteroids on glycolysis and basal respiration,
we characterized the bioenergetic proﬁle of SH-SY5Y neuroblastoma
cells, representing OCR versus ECAR under the different treatment
conditions (Fig. 3C). Notably, after treatment with the neurosteroid
Fig. 2.Neurosteroids increase ATP level in SH-SY5Y neuroblastoma cells. (A) ATP level was
signiﬁcantly increased after neurosteroid treatment for 24 h at a concentration of 10 nM
(white boxes) or 100 nM (gray boxes). (B) ATP level was measured after pre-treatment
of cells for 1 hwith either progesterone receptor antagonist RU-486 (100 nM), or estrogen
receptor antagonist ICI-182.780 (100 nM), or androgen receptor antagonist 2OH-
ﬂutamide (1 μM) and then treated for 24 h with the corresponding steroid agonist.
(C)Mitochondrialmembranepotential (MMP)was signiﬁcantly increased after neurosteroid
treatment for 24 h at a concentration of 10 nM (white boxes) or 100 nM (gray boxes). (A–C)
Values represent themean±SEM; n= 12–18 replicates of three independent experiments.
One-wayANOVAand post hocDunnetts'multiple comparison test versus control (untreated),
*P b 0.05; **P b 0.01; ***P b 0.001. Student unpaired t-test, &&P b 0.01; &&&P b 0.001. P;
progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 3α-androstanediol,
D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone, RU; RU-486, ICI; ICI-
182.780, ﬂut.; 2OH-ﬂutamide.
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tendency to increase both, glycolytic activity (ECAR) and basal respira-
tion (OCR).
A Pearson correlation was performed to study whether the ATP
levels correlated with OCR, ECAR or MMP (Fig. 4). A positive linear cor-
relation between ATP level and OCR (Fig. 4A), but not between ATP and
ECAR (Fig. 4B) or MMP (Fig. 4C) was detected, suggesting that the im-
provement in ATP production was preferentially linked to an increase
of mitochondrial respiration (oxygen consumption).
To investigate more deeply the effects of neurosteroids on mito-
chondrial OXPHOS, OCR was measured using permeabilized SH-SY5Y
cells, which allows the evaluation of different respiratory states and
the respiratory control ratio (RCR = state 3/state 4) (Fig. 5). Especially
testosterone signiﬁcantly up-regulated the mitochondrial respiratory
capacity by increasing the respiratory state 3 (ADP-dependent), state3 uncoupled (in the absence of proton gradient after injection of
FCCP) and the RCR (Fig. 5A–C). The treatment with DHEA (10 nM)
showed a similar effect on the RCR under these experimental conditions
(Table 1), while the rest of the tested steroid compounds had no bene-
ﬁcial effect on RCR. Thus, our ﬁndings suggest that neurosteroids
primarily act on basal respiration in neuroblastoma cells, and that tes-
tosterone and DHEA are additionally able to increase the capacity for
substrate oxidation (high RCR),which is importantwhen cells have spe-
ciﬁc or high energy demands.
Since SH-SY5Y cells and other cell lines are not as highly dependent
on OXPHOS as primary cell cultures to produce ATP [37], we investigat-
ed the action of neurosteroids on primary cell cultures from mouse
brain cortex. Data demonstrate that, except for the treatment with pro-
gesterone, the level of ATP was signiﬁcantly increased with at least one
of the two concentrations tested, ranging from a 27% increase after
treatment with estrone (100 nM) up to a 59% induced increase by
DHEA (10 nM) (Fig. 6A). Compared to the data obtained with SH-
SY5Y neuroblastoma cells (Fig. 2A), the magnitude of the rise in ATP
concentration was higher in the primary cortical cell culture (maximal
increase of 22.6% in SH-SH5Y cells versus 59.2% in primary neurons).
This result implies that primary cell cultures have a greater capacity to
produce ATP than neuroblastoma cells. Moreover, both concentrations
of allopregnanolone were able to increase ATP level in primary cells,
which was not the case in SH-SY5Y cells. Allopregnanolone mainly
acts as an allosteric positive modulator of GABAA receptor (GABAA-R).
To verify the implication of this receptor, we ﬁrst investigated whether
it was expressed in both cell types. We found that SH-SY5Y cells do not
express the GABAA-R subunits α1 and β2 that are involved in the
allopregnanolone binding site [38], in contrast to primary cortical neu-
rons (Suppl. Fig. 1), indicating that GABAA-R may be involved in the
modulation of bioenergetics by allopregnanolone in neurons.
To determine whether the increase in ATP level was due to an im-
provement of glycolytic activity ormitochondrial respiration in this cel-
lular model, we again performed a simultaneous real-time monitoring
of the ECAR and the OCR (Fig. 6B–D). We measured a signiﬁcant effect
on the OCR for most of the neurosteroids tested, starting with a 59% in-
crease after treatment with testosterone (10 nM) up to a 128% increase
induced by 3α-A (10 nM) (Fig. 6B). Again, themagnitude of changewas
higher compared to the neuroblastoma cell line (maximal increase of
26.5%). In parallel, we measured a slight, but not signiﬁcant, decrease
in the glycolytic activity, except for the treatment with progesterone
at 100 nM which in contrast induced a huge increase in the ECAR
(+51.% compared to the control condition) (Fig. 6C). The bioenergetic
proﬁle (OCR versus ECAR) revealed that after treatment with neuro-
steroids, the primary cortical neurons had the general tendency to
switch to a more aerobic state (Fig. 6D) by increasing their oxygen con-
sumption (OCR) and decreasing their glycolytic activity (ECAR), espe-
cially at the low concentration of 10 nM.
Taken together, these data indicate that in primary mouse neurons,
most of the neurosteroids from the tested panel were able to increase
ATP production via improvement of mitochondrial respiration.
3.2. Neurosteroids modulate the redox homeostasis
The increase of OXPHOS is often coupled with an increase in mito-
chondrial reactive oxygen species (mtROS) production [39,40]. Since
neurosteroids were able to signiﬁcantly increase mitochondrial respira-
tion, we investigated whether ROS levels were also increased within mi-
tochondria (mtROS) by measuring the oxidation of the ﬂuorescent dye
dihydrorhodamine 123 (DHR). All neurosteroids induced a signiﬁcant
dose-dependent increase in mtROS levels, ranging from a 43% increase
after DHEA treatment (10 nM) up to a 111.3% increase induced by testos-
terone (100 nM) (Fig. 7A). Moreover, the speciﬁc measure of mitochon-
drial superoxide anion radicals revealed that some of the ROS produced
were indeed superoxide anions (Table 1). However, the extent of
mtROS production, which in excess can lead to massive oxidative stress,
Table 1
Effects of neurosteroids on cellular bioenergetics in neuroblastoma cells.




10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM
ATP level 113.9⁎ 122.6⁎ 113.4⁎ 114.6⁎ 116⁎ 120.4⁎ 110.7⁎ 118⁎ 110.1⁎ 111.4⁎ 107.6⁎ 112.4⁎ 95.8 100.3
Cell proliferation 98.7 100.9 98.2 100.3 97.2 99.2 97.9 102.1 100.1 103.8 97.6 103.7 101.7 106.2⁎
MMP 120⁎ 108.2 118.5⁎ 118.8⁎ 120⁎ 119.2⁎ 128.1⁎ 119.9⁎ 123.2⁎ 109.8 132.2⁎ 119.9⁎ 111.5 114.2
Glycolysis 115.4 102.7 119.4⁎ 116.1⁎ 113.8 111.1 108.1 105.5 105.7 106.6 106.2 116.4⁎ 102.2 101.6
Mitochondrial respiration Basal 111 105.9 118.3⁎ 123.2⁎ 110.9 118.1⁎ 115.1⁎ 126.5⁎ 106.9 114.1⁎ 110.8⁎ 106.7 99.6 109.6
RCR 97.9 98.7 93.7 89.6 100.6 102.8 132.7⁎ 116.5⁎ 95.3 104 120.3⁎ 97.81 105.7 102.1
Mitochondrial ROS Total 108.4 151.7⁎ 122.9 160.8⁎ 121.8 171.3⁎ 145.2⁎ 211.3⁎ 148.4⁎ 182.8⁎ 143.9⁎ 200.6⁎ 151⁎ 207.2⁎
Superoxide 100.7 104⁎ 103 106.2⁎ 102.8 108⁎ 103.6⁎ 105.8⁎ 103.8⁎ 105.9⁎ 105⁎ 106.4⁎ 103.6⁎ 107.4⁎
MnSOD activity 110.6 128.6⁎ 120.7 136.6⁎ 128.7 141.9⁎ 137.4⁎ 149.3⁎ 134.7⁎ 127.6 135.3⁎ 128.1⁎ 128.7⁎ 147.4⁎
Mitochondrial redox state 105.7 110.6 108.1 108.9 104.1 109.2 109.9 113.6⁎ 109.8 109.1 104.2 113.3⁎ 91.7 102.5
Values represent the mean normalized on 100% of the control group (untreated).
⁎ Indicateswhen the percentage is signiﬁcantly different from the control group.MMP;mitochondrial membrane potential, RCR; respiratory control ratio, ROS; reactive oxygen species,
MnSOD; manganese superoxide dismutase.
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under those experimental conditions (data not shown).
Therefore, we next tested the antioxidant defense system in mito-
chondria. We quantitatively measured the activity of the manganese
superoxide dismutase activity (MnSOD), which is present within the
mitochondrial matrix. Indeed, MnSOD activity was signiﬁcantly in-
creased (Fig. 7B) after treatmentwith thewhole panel of neurosteroids,
ranging from a 28.6% (progesterone, 100 nM) up to a 49.3% increase
(testosterone, 100 nM). The increase in mtROS was paralleled by an in-
crease of antioxidant activity. In addition, mtROS level and MnSOD activ-
ity correlated with one another (Fig. 7C), suggesting that the increase of
MnSOD activity was substrate-dependent.
Finally, to verify whether themitochondrial redox environment was
impacted by this increase of ROS versus increase of antioxidant defenses,
SH-SY5Y cells stably transfectedwith a reporter gene coding for a redox
sensitive green ﬂuorescent protein (AR305 roGFP) located within mito-
chondria were treated with our panel of neurosteroids [28]. Fig. 7D dis-
plays the oxidation/reduction state in mitochondria, and indicates that,
despite a slight switch toward a more oxidized state, only testosterone
(100 nM)andDHEA (100nM) signiﬁcantlymodiﬁed the redox environ-
ment in mitochondria.
Taken together, our data indicate that neurosteroids increasedmito-
chondrial activity, which was paralleled by an enhancement in mtROS
levels. However, cell viability was still unchanged and the raise of
mtROS appeared to be at least in part compensated by an increase in
antioxidant activity, which in turn led to a slight switch to an oxidized
state within mitochondria.
4. Discussion
The aim of our study was to investigate the effects of seven neuro-
steroids on cellular bioenergetics and redox homeostasis in neuronal
cells. The key ﬁndings were that: i) the majority of these steroids in-
creased energy metabolism, mainly via an up-regulation of the mito-
chondrial activity and at least in part via receptor activation, and ii)
neurosteroids regulated redox homeostasis by increasing the antioxidant
activity as a compensatory mechanism to the ROS level enhancement
whichmight result from the acceleration in oxygen consumption accom-
panied by a greater electron leakage from the electron transport chain.
Additionally, each neurosteroid seems to have a speciﬁc bioenergetic pro-
ﬁle. The single proﬁles are delineated as pie charts for SH-SY5Y (Fig. 8A)
and mouse primary cortical neurons (Fig. 8B).
Remarkably, each steroid doesn't seem to act in the sameway on both
cell types. For example, allopregnanolone, which had no effects on ATP
level and basal respiration in SH-SY5Y cells, appeared to increase those
two parameters in primary neuronal cells. On the contrary, progesterone
was able to increaseATPproduction in SH-SY5Y cells, but showed a signif-
icant effect only on glycolysis in primary cells. One explanation could bethat SH-SY5Y cells and primary neuronal culture may exhibit steroid re-
ceptor expression proﬁles that are slightly different. Steroid receptor ex-
pression, such as that of progesterone, estrogen and androgen
receptors, has already been demonstrated in both SH-SY5Y cells
[29,30] and in mouse neurons [41–43], respectively. It is known
that allopregnanolone doesn't bind to a conventional steroid recep-
tor but mainly acts as a positive GABAA receptor (GABAA-R) alloste-
ric modulator that strengthens the effects of GABA. We found that
SH-SY5Y cells do not express GABAA-R unlike in the case of primary
neurons (Suppl. Fig. 1). This indicates that allopregnanolone may act
via GABAA-R to increase ATP level especially in primary neurons and
explains the lack of effect onATP in SH-SY5Y cells. Furthermore, other sig-
naling pathways and receptors may be involved in the effects of
allopregnanolone upon bioenergetics in primary cortical neurons, such
as the newly characterized pregnane xenobiotic receptor [44].
Moreover, it is known that proliferative cells and tumors have a net
tendency to use the cellular glycolysis to produce ATP instead of the
OXPHOS system. This phenomenon is called “Warburg effect” [37]. On
the contrary, primary neurons, which are differentiated cells, rely al-
most exclusively on the OXPHOS system to produce ATP and glycolysis
is really low (raw data not shown). Indeed, in the lattermodel, ATP level
appeared to be strictly coupled with the basal respiration. The bioener-
getic proﬁle of primary cortical cells revealed that neurosteroids
preferentially increased mitochondrial respiration and not the glycolytic
pathway, while both pathways were increased in SH-SY5Ycells
(Figs. 3C, 6D).
In the recent years, neurosteroids have emerged as new potential
therapeutic tools against neurodegeneration [45]. Among the steroids,
the family of sex steroid hormones is the most widely studied. They
are in the focus of research on neurodegenerative diseases since cogni-
tive decline and the risk to develop AD appear to be associated with an
age-related loss of sex hormones (e.g. estradiol, testosterone but also
progesterone) in both, women and men [25,46], a hypothesis largely
supported by epidemiological evidence [47]. In vitro and in vivo studies
demonstrated neuroprotective effects of sex hormones, particularly
with mitochondria proposed as the primary site of action of estradiol
[24,32,48,49]. Indeed, estrone (E1), estradiol (E2), and estriol (E3), are
known to play a fundamental role in the regulation of the female
metabolic system [50]. It has been reported that estrogens can regulate
mitochondrial metabolism by increasing the expression of glucose
transporter subunits and by regulating some enzymes involved in the
tricarboxylic acid cycle (TCA cycle) and glycolysis, which leads to an im-
provement in glucose utilization by cells (reviewed in [21]). Estrogens
seem also able to up-regulate genes coding for some electron transport
chain components such as subunits of mitochondrial complex I (CI), cy-
tochrome c oxidase (complex IV), and the F1 subunit of ATP synthase. In
line with these ﬁndings, our data demonstrated that both female sex
hormones, estradiol (E2) and estrone (E1), were able to increase ATP
Fig. 3. Neurosteroids positively regulate bioenergetic activity in SH-SY5Y neuroblastoma
cells. (A) Extracellular acidiﬁcation rate (ECAR) and (B) oxygen consumption rate (OCR)
were measured simultaneously using a Seahorse Biosciences XF24 Analyser in the same
experimental conditions. (C) Bioenergetic proﬁling of SH-SY5Y cells (OCR versus ECAR) re-
vealed increased metabolic activity after treatment with neurosteroids. Values represent
the mean of each group (mean of the ECAR in abscissa/mean of the OCR in ordinate)
normalized to the untreated control group (=100%). (A–C) Values represent the
mean ± SEM; n = 12–18 replicates of three independent experiments. One-way ANOVA
and post hoc Dunnetts' multiple comparison test versus control (untreated), *P b 0.05;
**P b 0.01; ***P b 0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A;
3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone.
Fig. 4. ATP levels did correlate with basal mitochondrial respiration. Graph representing
ATP levels in abscissa versus (A)OCR or (B) ECAR or (C)MMP in ordinate. Values represent
the mean of each treatment group normalized to the control group (=100%). Pearson
correlation r = 0.5074, R2 = 0.2575, P = 0.0032. OCR; oxygen consumption rate, ECAR;
extracellular acidiﬁcation rate; MMP; mitochondrial membrane potential.
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note, the increase of ATP levels induced by E2 and E1 was abolished in
the presence of ICI-182.780, an estrogen receptor (α and β) antagonist
(Fig. 2B) suggesting that estrogens, such as E2 and E1, may act via these
receptors to up-regulate genes involved in cellular bioenergetics, as
mentioned above. Estradiol seemed to be more potent that estrone,
because both concentrations (10 nM and 100 nM) were effective to in-
crease ATP levels and mitochondrial respiration. In addition, estradiol
was able to regulate glycolysis. This difference can be explained by the
observation that, despite estrone's capability as an estrogenic com-
pound, it is about 10 times less estrogenic than estradiol [21]. The
same ﬁnding was observed in primary neurons (Fig. 8B).
Regarding the predominantly male hormone testosterone, we
witnessed an increase in ATP levels, basal respiration andmitochondrialmembrane potential in neuroblastoma cells (Fig. 8A). Moreover, testos-
terone was also the only steroid besides DHEA inducing an acceleration
of the respiratory control ratio (RCR), an indicator of the capacity for
substrate oxidation (high RCR),which is importantwhen cells have spe-
ciﬁc or high energy demands. The role of androgens on mitochondrial
function, especially testosterone, has received little attention up to
now, compared to the estrogens. Only one study demonstrated a similar
effect of testosterone on MMP [51]. Furthermore, it has been proposed
that estradiol and testosterone can regulate energy production by in-
ducing nuclear and mitochondrial OXPHOS genes, since the subunits
of mitochondrial chain complexes are encoded by the nuclear and the
mitochondrial genome, respectively, and both contain hormone re-
sponsive elements [52]. Again, thoseﬁndings are in linewith our results,
since we have shown that the increase of ATP levels was blocked in the
presence of estrogen and androgen receptor antagonists (Fig. 2B).
Progesterone is the second main female sex hormone but it is also a
precursor for estrogens and androgens. Progesterone, and its 3α–5α-
derivate allopregnanolone (or 3α, 5α-tetrahydroprogesterone) as well
as 3α-androstanediol, seem to play a role in mood modulation. Their
Fig. 5. Testosterone increased mitochondrial respiratory capacity. (A) Oxygen consump-
tion rate (OCR), was measured on permeabilized SH-SY5Y cells after treatment with tes-
tosterone for 24 h, using a XF24 Analyser (Seahorse Bioscience). The sequential injection
of mitochondrial inhibitors is indicated by arrows (see details in the Materials and
methods section). (B) Values corresponding to the different respiratory states are repre-
sented as mean ± SEM (n = 15–18 replicate of three independent experiments/group)
andwere normalized to the basal respiration of the control group (=100%). (C) The respi-
ratory control ratio (RCR= State 3/State 4o), which reﬂects themitochondrial respiratory
capacity, was increased by testosterone. Student unpaired t-test, *P b 0.05. T 10 nM;
testosterone at a concentration of 10 nM, T 100 nM; testosterone at a concentration of
100 nM, O; oligomycin, F; FCCP, R/A; rotenone/antimycin A.
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and more recently AD is currently under investigation [35]. In the pres-
ent study, we demonstrated that progesterone increased ATP levels and
MMP without signiﬁcant effects on basal respiration in neuroblastoma
cells (Fig. 8A). An increase in glycolysis was also observed after treat-
ment in the primary neurons (Fig. 8B). Again, the up-regulatory effect
of progesterone on ATP levelswas shut down in the presence of the pro-
gesterone receptor antagonist RU-486 (Fig. 2B), suggesting that proges-
terone also modulates cellular bioenergetics by regulating gene
expression via a progesterone nuclear receptor. Studies performed on
ovariectomized rats revealed that a 24 h treatment with progesterone
(subcutaneous injection, 30 μg/kg) increased OXPHOS capacity in iso-
lated mitochondria, in part by enhancing cytochrome c oxidase activity
and expression [32]. Interestingly, the increase of OXPHOS capacity was
suppressed by a co-treatmentwith estradiol and progesterone, suggest-
ing a competitive mode of action between both steroids. Another study
using wobbler ALS (amyotrophic lateral sclerosis) model mice showed
that progesterone was able to normalize the deﬁcits in mitochondrial
complex I activity observed in motor neurons of the cervical spinal
cord [56]. Because progesterone seems to have different functional ef-
fects, one can speculate that its action on mitochondrial respiration
may be distinct to speciﬁc nerve cell populations.
Allopregnanolone and 3α-androstanediol have a distinct mode of
action compared to sex hormones because they mainly act on mem-
brane receptors (allosteric modulator of GABAA-R) and not nuclear
receptors [57]. Their effects on mitochondrial bioenergetics cannot be
explained by a direct regulation of genes involved in the OXPHOS
system as previously proposed for sex hormones. In our study, 3α-
androstanediol showed a similar effect compared to progesterone in
the neuronal cell line, but was also able to signiﬁcantly increasethe basal respiration (at 100 nM) (Fig. 8A). Both concentrationswere ef-
fective to increase ATP and respiration in primary cells (Fig. 8B).
Allopregnanolone signiﬁcantly regulated ATP levels and basal respiration
only in primary neurons, whereas no effect was detected in the
neuroblastoma cell line. Based on those observations, we can speculate
that: i) GABAA-R is involved in the up-regulatory effect of allopreg-
nanolone onATP levels in primary cells because no increasewas observed
in SH-SY5Y cells lacking of this receptor (Suppl. Fig. 1); and ii) 3α-
androstanediol could act via androgen receptor because its effect on ATP
levels was abolished in the presence of an androgen receptor antagonist
(Fig. 2B). However, further investigations will be required to understand
the exact underlying mechanisms. Besides, due to the high complexity
of the neurosteroid pathway synthesis, it is difﬁcult to conclude that
the effect which we observed on bioenergetics is due to the tested
neurosteroid itself, or to one of its metabolites, because they all belong
to crisscross pathways (Fig. 1). However, since blocking progesterone,
estrogen and androgen receptors abolishes the effects of their respective
agonists, we have good evidence that the neurosteroids themselves ex-
hibit themode of action. In the sameway, we can exclude that progester-
one is acting via itsmetabolite allopregnanolone because the latter has no
effects on bioenergetics in SH-SY5Y cells. Nevertheless, it is also possible
that 3α-androstanediol doesn't act directly on androgen receptors but is
converted in dihydrotestosterone, another testosterone metabolite
which has high afﬁnity for this receptor. In a similar way, DHEA can be
converted in androgens and estrogens andmay act via the corresponding
steroid nuclear receptor.
DHEA (dehydroepiandrosterone) was the ﬁrst neurosteroid identi-
ﬁed in 1981 [11], and its physiological action involves both genomic
and non-genomic mechanisms, in part via activation of androgen/
estrogen receptors and allosteric modulation of NMDA receptors, re-
spectively [58]. Human studies showed an age-related decrease in
DHEA levels in the brain and in the blood in relation to the age-
associated cognitive decline [17,59]. In vitro, we showed that DHEA en-
hanced ATP levels and basal respiration in primary neurons (Fig. 8B). A
similar effect was observed in the neuronal cell line with an additional
increase in MMP, glycolysis and RCR (Fig. 8A, Table 1). In agreement
with our ﬁndings, DHEA was able to improve mitochondrial respiration
in the brain of old rats (18–24 months)which exhibited a decline inmi-
tochondrial function when compared to young rats (8–10 weeks) [60].
More speciﬁcally, DHEA stimulated the respiratory state 3 in old rats
which consequently was similar to that of untreated young rats. Fur-
thermore, DHEA increased cytochrome c content in young and old
mouse brains and enhanced mitochondrial dehydrogenase activities.
Thus, the different bioenergetic proﬁles we observed after treatment
with our panel of steroids could be explained by their distinct abilities to
directly or indirectly regulate the transcription of genes involved in
glycolysis and oxidative phosphorylation (probably, via steroid nuclear
receptors), but also the content and activity of mitochondrial respirato-
ry complexes. Further investigations are required to determine in more
detail which genes are involved in these processes.
Mitochondria are known to be paradoxical organelles. They can be
compared to a double-edged sword that, on one hand, produces the en-
ergy necessary for cell survival, and on the other hand, induces the for-
mation of ROS that can be harmful for cells when produced in excess
with mitochondria as the ﬁrst target of toxicity [39,40]. In our study,
the increase in ATP appeared to be coupled to an increase in MMP and
improved basal respiration (Fig. 8A). In parallel, we detected higher
mitochondrial ROS levels, supporting the hypothesis that increased mi-
tochondrial activity generates more ROS. The only exception was ob-
served after treatment with allopregnanolone where we detected
more ROS but no increase in ATP level, MMP, or basal respiration. We
can speculate that, in this model, allopregnanolone might be able to in-
crease ROS-producing metabolic functions via other mechanisms. But
with regard to the other neurosteroids, the increase of mitochondrial
ROS was paralleled by an increase in MnSOD activity. The MnSOD is
located in the mitochondrial matrix and represents one of the ﬁrst
Fig. 6. Neurosteroids up-regulated the bioenergetic activity in primary cortical cells. (A) ATP level was signiﬁcantly increased after neurosteroid treatment (24 h) at a concentration of
10 nM (white boxes) and 100 nM (gray boxes). (B) Oxygen consumption rate (OCR) and (C) extracellular acidiﬁcation rate (ECAR) were measured simultaneously using a Seahorse
Biosciences XF24 Analyser under the same experimental conditions. (D) Bioenergetic proﬁle of primary cortical cells (OCR versus ECAR) revealed an increased aerobic activity (O2
consumption) after treatment with neurosteroids. Values represent the mean of each group (mean of the ECAR in abscissa/mean of the OCR in ordinate) and were normalized to the
control group (100%). (A–C) Values represent the mean ± SEM, n = 4–6 replicates of three independent experiments/group, and were normalized to the control group (=100%).
One-wayANOVA and post hocDunnetts' multiple comparison test versus control (untreated), *P b 0.05; **P b 0.01; ***P b 0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone,
3α-A; 3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone.
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proved activity could be in part explained by an up-regulation of gene
expression and protein level of MnSOD. Indeed, in studies which fo-
cused on antioxidant effects of steroids in ovariectomized female rats,
an increase of MnSOD protein level has been observed after treatment
with estradiol or progesterone [32], whereas DHEA preferentially up-
regulated the expression of Cu/ZnSOD [31]. In orchiectomized male
rats, testosterone was also able to increase MnSOD protein level
compared to the control (sham operated) [62]. A similar observation
was made in the wobbler ALS mouse model, where MnSOD expression
was elevated after treatment with progesterone [56].
In our study, the correlation between mitochondrial ROS level and
MnSOD activity implies that the increase of enzymatic SOD activity
might be preferentially substrate-dependent, but can be explained, at
least in part, by an up-regulation of gene expression.
Based on our observation, one can speculate that pre-treatmentwith
neurosteroids may exert a protective action against oxidative stress,
possibly through a preconditioning mechanism via their ability to
increase antioxidant defenses (i.e. MnSOD activity). However, in an
already oxidized environment, the presence of neurosteroids may be
deleterious for cells because they also appear to further increase ROS
production. This observation reinforces the “critical window hypothe-
sis” of the therapeutic use of steroids as debated recently with regard
to the hormone replacement therapy in post-menopausal women [63]
and implies that this kind of therapy should begin at an age when the
redox system is still balanced, thus favoring the reference postulating
early onset administration.
It is known that some neurosteroid levels decline during aging
and are further modiﬁed in neurodegenerative conditions (i.e. ADand PD). In addition, mitochondrial dysfunction has been well-
documented in aging and age-related neurodegenerative diseases
[64]. Steroids offer interesting therapeutic opportunities for
promoting successful aging because of their pleiotropic effects
in the nervous system. Our ﬁndings highlight, for the ﬁrst time,
up-regulatory effects of neurosteroids upon the neuronal bioener-
getic activity via up-regulation of the mitochondrial oxygen
consumption as a common mechanism underlying neurosteroid
action. In addition, these steroids can modulate the redox homeo-
stasis, by balancing the increase of ROS production via improved
mitochondrial antioxidant activity (Fig. 9). Thus, our results
provide new insights in re-deﬁning the biological model of how
neurosteroids control neuronal functions. Because each steroid
appeared to have a speciﬁc proﬁle in bioenergetic outcome
and redox homeostasis, the underlying mechanisms have to be
elucidated in more details in the future, as well as those in models
of neurodegenerative diseases, such as AD.
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Fig. 7. Neurosteroids modulate the mitochondrial redox environment in SH-SY5Y neuroblastoma cells. (A) Mitochondrial reactive oxygen species (mtROS) levels were signiﬁcantly in-
creased after neurosteroid treatment (24 h) at a concentration of 10 nM (white boxes) and 100 nM (gray boxes). (B) This increase was accompanied by an up-regulation of manganese
superoxide dismutase activity (MnSOD). (C) A positive correlation was observed between ROS levels and MnSOD activity. (D) Using a reporter gene coding for a redox sensitive green
ﬂuorescent protein (AR305 roGFP) located within mitochondria, the mitochondrial redox state underwent a switch to a more oxidized state after neurosteroid treatment compared to
the untreated control. (A, B) Values represent the mean ± SEM and were normalized to the corresponding untreated control group (=100%). (C) Values represent the mean of each
group (mean of the mitochondrial ROS level in abscissa/mean of the MnSOD activity in ordinate) normalized to the untreated control group (=100%). Pearson correlation r = 0.7096,
R2 = 0.5035, P = 0.0022. (D) Values represent the mean ± SEM of the ratio “oxidized state/reduced state”, n = 8–15 replicates of three independent experiments/group. Values were
normalized to the control group (=100%). One-way ANOVA and post hoc Dunnett's multiple comparison test versus control (untreated), *P b 0.05; **P b 0.01; ***P b 0.001; P; progester-
one, E2; estradiol, E1; estrone, T; testosterone, 3a-A; 3a-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone, Ox.; oxidized environment, Red.; reduced
environment.
Fig. 8. Different action proﬁle of neurosteroids on cellular bioenergetics. Representative diagrams of the effects of neurosteroids on the bioenergetic activity (ATP level, basal respiration,
glycolysis, MMP) and the modulation ofmitochondrial redox environment (mtROS levels, MnSOD activity, redox state) in SH-SH5Y neuroblastoma cells (A), and the bioenergetic activity
in primary cortical cells (B). No effect is represented inwhite color. A signiﬁcant increase of the respective parameter ismarked either in yellow (signiﬁcant only at 10 nM), blue (signiﬁcant
only at 100 nM), or green (signiﬁcant at both concentrations). mtROS; mitochondrial reactive oxygen species, MMP; mitochondrial membrane potential, MnSOD;manganese superoxide
dismutase activity.
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Fig. 9. Schematic representation of the effects of neurosteroids on mitochondrial bioenergetics and redox environment in SH-SH5Y neuroblastoma cells. * indicates that the effect was
similar to that observed in primary cortical cells. ETC; electron transport chain, TCA; tricyclic acid, MnSOD; manganese superoxide dismutase, ROS; reactive oxygen species, MMP;
mitochondrial membrane potential.
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